Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
CEMI's Cash to Debt is ranked higher than
85% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.74 vs. CEMI: No Debt )
CEMI' s 10-Year Cash to Debt Range
Min: 0.02   Max: No Debt
Current: No Debt

Equity to Asset 0.86
CEMI's Equity to Asset is ranked higher than
91% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.63 vs. CEMI: 0.86 )
CEMI' s 10-Year Equity to Asset Range
Min: -2.07   Max: 0.86
Current: 0.86

-2.07
0.86
Interest Coverage 171.60
CEMI's Interest Coverage is ranked higher than
69% of the 98 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 116.56 vs. CEMI: 171.60 )
CEMI' s 10-Year Interest Coverage Range
Min: 28.82   Max: 9999.99
Current: 171.6

28.82
9999.99
F-Score: 5
Z-Score: 6.33
M-Score: -3.16
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 15.41
CEMI's Operating margin (%) is ranked higher than
90% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.84 vs. CEMI: 15.41 )
CEMI' s 10-Year Operating margin (%) Range
Min: -93.86   Max: 15.41
Current: 15.41

-93.86
15.41
Net-margin (%) 15.04
CEMI's Net-margin (%) is ranked higher than
92% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.33 vs. CEMI: 15.04 )
CEMI' s 10-Year Net-margin (%) Range
Min: -93.74   Max: 32.02
Current: 15.04

-93.74
32.02
ROE (%) 43.26
CEMI's ROE (%) is ranked higher than
98% of the 163 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.27 vs. CEMI: 43.26 )
CEMI' s 10-Year ROE (%) Range
Min: -2150   Max: 49.69
Current: 43.26

-2150
49.69
ROA (%) 27.66
CEMI's ROA (%) is ranked higher than
98% of the 177 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.84 vs. CEMI: 27.66 )
CEMI' s 10-Year ROA (%) Range
Min: -1842.86   Max: 40.09
Current: 27.66

-1842.86
40.09
ROC (Joel Greenblatt) (%) 77.55
CEMI's ROC (Joel Greenblatt) (%) is ranked higher than
94% of the 175 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.14 vs. CEMI: 77.55 )
CEMI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -4366.67   Max: 77.55
Current: 77.55

-4366.67
77.55
Revenue Growth (%) 18.10
CEMI's Revenue Growth (%) is ranked higher than
93% of the 147 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.80 vs. CEMI: 18.10 )
CEMI' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 26.4
Current: 18.1

0
26.4
EBITDA Growth (%) -19.00
CEMI's EBITDA Growth (%) is ranked higher than
56% of the 124 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.90 vs. CEMI: -19.00 )
CEMI' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 48.7
Current: -19

0
48.7
EPS Growth (%) -40.20
CEMI's EPS Growth (%) is ranked higher than
53% of the 129 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.30 vs. CEMI: -40.20 )
CEMI' s 10-Year EPS Growth (%) Range
Min: -67.1   Max: 54.2
Current: -40.2

-67.1
54.2
» CEMI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

CEMI Guru Trades in

Q2 2012

CEMI Guru Trades in Q2 2012

John Keeley 15,000 sh (New)
» More
Q3 2012

CEMI Guru Trades in Q3 2012

John Keeley 15,000 sh (unchged)
» More
Q4 2012

CEMI Guru Trades in Q4 2012

John Keeley Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with CEMI

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Keeley 2012-12-31 Sold Out 0.0016%$4.05 - $5.26 $ 3.47-24%0
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.70
CEMI's P/B is ranked higher than
94% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.79 vs. CEMI: 1.70 )
CEMI' s 10-Year P/B Range
Min: 0.88   Max: 20.4
Current: 1.7

0.88
20.4
P/S 1.30
CEMI's P/S is ranked higher than
91% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.55 vs. CEMI: 1.30 )
CEMI' s 10-Year P/S Range
Min: 0.19   Max: 11.85
Current: 1.3

0.19
11.85
PFCF 43.30
CEMI's PFCF is ranked higher than
80% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. CEMI: 43.30 )
CEMI' s 10-Year PFCF Range
Min: 8   Max: 97.6
Current: 43.3

8
97.6
EV-to-EBIT 174.17
CEMI's EV-to-EBIT is ranked higher than
74% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. CEMI: 174.17 )
CEMI' s 10-Year EV-to-EBIT Range
Min: 8.9   Max: 174.1
Current: 174.17

8.9
174.1
Shiller P/E 15.60
CEMI's Shiller P/E is ranked higher than
99% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. CEMI: 15.60 )
CEMI' s 10-Year Shiller P/E Range
Min: 13.64   Max: 19
Current: 15.6

13.64
19
Current Ratio 5.26
CEMI's Current Ratio is ranked higher than
85% of the 177 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.67 vs. CEMI: 5.26 )
CEMI' s 10-Year Current Ratio Range
Min: 0.01   Max: 58
Current: 5.26

0.01
58
Quick Ratio 4.15
CEMI's Quick Ratio is ranked higher than
82% of the 177 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.49 vs. CEMI: 4.15 )
CEMI' s 10-Year Quick Ratio Range
Min: 0.01   Max: 58
Current: 4.15

0.01
58

Valuation & Return

vs
industry
vs
history
Price/Net Cash 5.60
CEMI's Price/Net Cash is ranked higher than
93% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. CEMI: 5.60 )
CEMI' s 10-Year Price/Net Cash Range
Min: 3.33   Max: 94.8
Current: 5.6

3.33
94.8
Price/Net Current Asset Value 3.20
CEMI's Price/Net Current Asset Value is ranked higher than
96% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. CEMI: 3.20 )
CEMI' s 10-Year Price/Net Current Asset Value Range
Min: 2.84   Max: 67.2
Current: 3.2

2.84
67.2
Price/Tangible Book 1.60
CEMI's Price/Tangible Book is ranked higher than
96% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 7.20 vs. CEMI: 1.60 )
CEMI' s 10-Year Price/Tangible Book Range
Min: 1.29   Max: 17.68
Current: 1.6

1.29
17.68
Price/DCF (Projected) 1.50
CEMI's Price/DCF (Projected) is ranked higher than
92% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. CEMI: 1.50 )
CEMI' s 10-Year Price/DCF (Projected) Range
Min: 1.49   Max: 28
Current: 1.5

1.49
28
Price/Median PS Value 0.90
CEMI's Price/Median PS Value is ranked higher than
85% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.41 vs. CEMI: 0.90 )
CEMI' s 10-Year Price/Median PS Value Range
Min: 0.21   Max: 7.42
Current: 0.9

0.21
7.42
Earnings Yield (Greenblatt) 0.60
CEMI's Earnings Yield (Greenblatt) is ranked lower than
58% of the 118 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.20 vs. CEMI: 0.60 )
CEMI' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.6   Max: 11.2
Current: 0.6

0.6
11.2
Forward Rate of Return (Yacktman) -5.23
CEMI's Forward Rate of Return (Yacktman) is ranked higher than
63% of the 147 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.93 vs. CEMI: -5.23 )
CEMI' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -171.3   Max: -6.1
Current: -5.23

-171.3
-6.1

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, DGX, LIFE, ENZ, IDXX » details
Chembio Diagnostics, Inc. was formed in 1985. On May 5, 2004, the Company completed a merger with Chembio Diagnostic Systems Inc. through which Chembio Diagnostics Systems Inc. became the Company's wholly-owned subsidiary, and through which the management and business of Chembio Diagnostic Systems Inc. became its management and business. As part of this transaction, it changed its name to Chembio Diagnostics, Inc. The Company with its subsidiaries develops, manufacture and market diagnostic tests that detect infectious diseases. The Company's main products presently commercially available are four rapid tests for the detection of HIV antibodies in whole blood, serum and plasma samples, all of which Employ lateral flow technology, and two of which were approved by the FDA in 2006. The Company's products are sold to medical laboratories and hospitals, governmental and public health entities, non-governmental organizations, medical professionals and retail establishments both domestically and internationally. The Company's products are sold either under its STAT PAK, SURE CHECK or DPP registered trademarks and/or the private labels of its marketing partners, such as is the case with the Inverness Clearview label for the Company's HIV tests in the United States. The main component of the Company's revenue growth was increased sales of its HIV tests and related components. The FDA approved its Pre-Market Applications for its SURE CHECK HIV 1/2 (and also now Inverness' Clearview Complete HIV 1/2) and HIV 1/2 STAT-PAK (now Inverness' Clearview(r) HIV 1/2 STAT-PAK in the United States only) products. The Company also has commercially available lateral flow tests for Chagas Disease and also a line of tests for the detection of tuberculosis in humans and certain animal species. All of the Company's commercially available current products Employ either in-licensed lateral flow technology or its own patented Dual Path Platform (DPP) technology. The Company's HIV tests are qualitative (reactive/non-reactive) tests. The diagnostics industry is a multi-billion dollar international industry and is intensely competitive. Many of its competitors are substantially larger and have greater financial, research, manufacturing and marketing resources. The manufacturing and marketing of the Company's existing and proposed diagnostic products are regulated by the United States Food and Drug Administration ('FDA'), United States Department of Agriculture ('USDA'), certain state and local agencies, and/or comparable regulatory bodies in other countries.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide